- Home
- IVDA vs NLSP Comparison
IVDA vs NLSP Comparison
Compare IVDA & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVDA
- NLSP
- Stock Information
- Founded
- IVDA 2003
- NLSP 2015
- Country
- IVDA United States
- NLSP Switzerland
- Employees
- IVDA N/A
- NLSP N/A
- Industry
- IVDA Computer Software: Prepackaged Software
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- IVDA Technology
- NLSP Health Care
- Exchange
- IVDA Nasdaq
- NLSP Nasdaq
- Market Cap
- IVDA 6.7M
- NLSP 12.4M
- IPO Year
- IVDA N/A
- NLSP 2021
- Fundamental
- Price
- IVDA $2.36
- NLSP $2.20
- Analyst Decision
- IVDA
- NLSP
- Analyst Count
- IVDA 0
- NLSP 0
- Target Price
- IVDA N/A
- NLSP N/A
- AVG Volume (30 Days)
- IVDA 84.2K
- NLSP 265.8K
- Earning Date
- IVDA 08-13-2025
- NLSP 07-22-2025
- Dividend Yield
- IVDA N/A
- NLSP N/A
- EPS Growth
- IVDA N/A
- NLSP N/A
- EPS
- IVDA N/A
- NLSP N/A
- Revenue
- IVDA $7,148,449.00
- NLSP N/A
- Revenue This Year
- IVDA $340.48
- NLSP N/A
- Revenue Next Year
- IVDA N/A
- NLSP N/A
- P/E Ratio
- IVDA N/A
- NLSP N/A
- Revenue Growth
- IVDA 54.15
- NLSP N/A
- 52 Week Low
- IVDA $1.27
- NLSP $1.30
- 52 Week High
- IVDA $8.05
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- IVDA 57.55
- NLSP 43.99
- Support Level
- IVDA $2.02
- NLSP $2.06
- Resistance Level
- IVDA $2.57
- NLSP $2.33
- Average True Range (ATR)
- IVDA 0.19
- NLSP 0.25
- MACD
- IVDA 0.04
- NLSP -0.07
- Stochastic Oscillator
- IVDA 70.99
- NLSP 7.84
About IVDA Iveda Solutions Inc.
Iveda Solutions Inc offers smart city technologies globally, offering advanced AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients worldwide. The smart cities market, as well as the AI and IoT segments, are poised for significant growth in the coming years. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products).
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.